Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial
Year: 2026
Type: article
Abstract: The phase 3 COMPASSION-16 trial demonstrates significant progression-free survival (PFS) and overall survival (OS) benefits with cadonilimab plus standard therapy in patients with persistent, recurrent, or metastatic cervical cancer. This analysis aims to assess efficacy outcomes in patient subgroups of COMPASSION-16. The dual primary endpoints of COMPASSION-16 are PFS, assessed by the blinded independent central review (BICR) according to RECIST version 1.1, and OS. The secondary endpoint is objective response rate. In this subgroup analysis, the PFS, OS and objective response rate are evaluated in subgroups including bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), metastatic disease at baseline, platinum use, and age. With median follow-up of 25.6 months, hazard ratios (HRs) for PFS favour cadonilimab group in all subgroups. Moreover, the addition of cadonilimab is also associated with prolonged overall survival. This subgroup analysis confirms that improvements in progression-free and overall survival are consistent with the primary results of the COMPASSION-16 study across diverse patient profiles. The COMPASSION16 trial showed survival benefits of cadonilimab plus standard therapy in advanced cervical cancer. Here, subgroup analysis confirms consistent progression-free and overall survival improvements across diverse patient profiles.
Source: Nature Communications
Authors: Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yuzhi Li, Chunyan Wang, Guiling Li, Yifeng Wang, Dapeng Li, Ying Tang, Mei Pan, Hongyi Cai, Weihu Wang, Bing Yang, Hua Qian, Qiuhong Tian, Desheng Yao, Ying Cheng, Bing Wei, Xiumin Li, Tao Wang, Min Hao, Xiaohong Wang, Tiejun Wang, Chang Liu, Hong Zhu, Lijing Zhu, Xianling Liu, Yunxia Li, Lihong Chen, Qingshan Li, Xiaojian Yan, Fei Wang, Hongbing Cai, Yunyan Zhang, Zhiqing Liang, Funan Liu, Yi Huang, Bairong Xia, Pengpeng Qu, Genhai Zhu, Youguo Chen, Kun Song, Meili Sun, Zhengzheng Chen, Qiang Zhou, Lina Hu, Guzhalinuer Abulizi, Hongyan Guo, Sihai Liao, Yijing Ye, Ping Yan, Qiu Tang, Guoping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Zhongmin M. Wang, Baiyong Li, Michelle Xia, Xiaohua Wu
Institutions: Fujian Medical University, Fujian Provincial Cancer Hospital, Central South University, Hunan Cancer Hospital, Zhejiang Cancer Hospital, Southwest Medical University, Affiliated Hospital of Southwest Medical University, Shandong First Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Fourth Hospital of Hebei Medical University, Ningxia Medical University, Ningxia Medical University General Hospital, First Affiliated Hospital of Bengbu Medical College, Liaoning Cancer Hospital & Institute, Wuhan Union Hospital, Zhujiang Hospital, Southern Medical University, Chongqing University, Jiangxi Maternal and Child Health Hospital, Wuhan University, Gansu Provincial Hospital, Zhongnan Hospital of Wuhan University, Peking University Cancer Hospital, Zunyi Medical University, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Nanjing Medical University, First Affiliated Hospital of Nanchang University, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Jilin Province Tumor Hospital, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Jilin University, First Affiliated Hospital of Xi'an Jiaotong University, Second Affiliated Hospital of Jilin University, Shanxi Medical University, Second Hospital of Shanxi Medical University, Henan University of Science and Technology, First Affiliated Hospital of Henan University of Science and Technology, First Hospital of Lanzhou University, Xiangya Hospital Central South University, Nanjing Drum Tower Hospital, Second Xiangya Hospital of Central South University, Shaanxi Provincial People's Hospital, Chengde Medical University, Affiliated Hospital of Chengde Medical College, First Affiliated Hospital of Wenzhou Medical University, Shandong Provincial Hospital, Harbin Medical University, Army Medical University, First Hospital of China Medical University, China Medical University, Hubei Cancer Hospital, Tianjin Central Hospital of Gynecology Obstetrics, Hainan General Hospital, First Affiliated Hospital of Soochow University, Qilu Hospital of Shandong University, Jinan Central Hospital, University of Science and Technology of China, Second Affiliated Hospital of Chongqing Medical University, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, Peking University Third Hospital, Guangdong Medical College, Zhongshan People's Hospital, Hebei General Hospital, Women's Hospital, School of Medicine, Zhejiang University, Zhejiang University, First Affiliated Hospital of Anhui Medical University, Fudan University Shanghai Cancer Center
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W7135239035